Back to Authors

Gandhi, Manish

0000-0001-7210-1909

Mayo Clinic

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Citations 27

Characterisation of the Novel HLA‐DPA1*03:25 Allele by Next Generation Sequencing

HLA | May 29, 2026 | Volume: 107 | Issue: 6 | Pages: No page available

10.1111/tan.70773 | PMID 42210829

ABSTRACT HLA‐DPA1*03:25 is characterised by a single nucleotide substitution in codon 96 in exon 3.
Characterisation of the Novel HLA‐A*03:535 Allele by Next Generation Sequencing and Oxford Nanopore Sequencing

HLA | May 22, 2026 | Volume: 107 | Issue: 5 | Pages: No page available

10.1111/tan.70761 | PMID 42170734

ABSTRACT The novel HLA‐A*03:535 allele is characterised by a single nucleotide substitution in exon 1.
Characterisation of the Novel HLA‐DQB1*03:609 Allele by Next Generation Sequencing

HLA | May 15, 2026 | Volume: 107 | Issue: 5 | Pages: No page available

10.1111/tan.70752 | PMID 42138570

ABSTRACT HLA‐DQB1*03:609 is characterised by a single nucleotide substitution in codon 132 in exon 3.
Genomic Confirmation of HLA‐C*12:68 by Next Generation Sequencing

HLA | May 6, 2026 | Volume: 107 | Issue: 5 | Pages: No page available

10.1111/tan.70740 | PMID 42089409

ABSTRACT HLA‐C*12:68 is characterised by a single nucleotide substitution in codon 62 in exon 2.
Genomic Confirmation of HLA‐B*47:14 by Next Generation Sequencing

HLA | May 5, 2026 | Volume: 107 | Issue: 5 | Pages: No page available

10.1111/tan.70737 | PMID 42083306

ABSTRACT HLA‐B*47:14 is characterised by a single nucleotide substitution in codon 97 of exon 3.
Genomic Confirmation of HLA‐DQB1*03:506:01:01 , by Next Generation Sequencing

HLA | April 21, 2026 | Volume: 107 | Issue: 4 | Pages: No page available

10.1111/tan.70726 | PMID 42059316

ABSTRACT The HLA‐DQB1*03:506:01:01 allele is characterised by a single nucleotide substitution in codon 130 in exon 3.
Genomic Confirmation of HLA‐C*14:84 , by Next Generation Sequencing

HLA | April 20, 2026 | Volume: 107 | Issue: 4 | Pages: No page available

10.1111/tan.70733 | PMID 42007826

ABSTRACT The HLA‐C*14:84 allele is characterised by a single nucleotide substitution in codon 181 in exon 3.
Genomic Extension of HLA‐C*03:31 , by Next‐Generation Sequencing

HLA | March 18, 2026 | Volume: 107 | Issue: 3 | Pages: No page available

10.1111/tan.70655 | PMID 41847913

ABSTRACT The HLA‐C*03:31 allele is characterised by a nucleotide substitution at genomic DNA position 400 in exon 2.
Hemolysis or vitamin B12? Unveiling the impostor

Transfusion | March 19, 2025 | Volume: 65 | Issue: 5 | Pages: 797-798

10.1111/trf.18219 | PMID 40105875

An in silico simulation of the frequency of administering HLA‐incompatible low titer group O whole blood units when the donor pool includes unscreened female donors

Transfusion | February 5, 2025 | Volume: 65 | Issue: S1 | Pages: No page available

10.1111/trf.18141 | PMID 39908301

AbstractBackgroundAs low titer group O whole blood (LTOWB) increases in popularity, blood centers are finding innovative ways of maintaining the supply. One potential way is collecting LTOWB from parous female donors without testing for HLA antibodies. This in silico simulation predicted the risk of an LTOWB unit containing an HLA antibody and the subsequent risk for an HLA‐incompatible transfusion.MethodsAn LTOWB blood bank with 1 million units was simulated consisting of male, nulliparous, and parous female donors. The proportion of each donor type was modeled after the sex distribution at US blood centers. The parity of female donors was calculated based on the average number of live births per female depending on her age. HLA‐alloimmunization risk was determined by her parity status. The HLA haplotypes of the simulated recipients were derived from the 100 most common HLA haplotypes in the US National Marrow Registry Program database. The proportion of different race/ethnic groups in the US was used to simulate 100,000 LTOWB recipients to whom between 1 and 10 units were administered.ResultsOverall, the risk of an LTOWB unit containing at least one HLA antibody was 12.2% and the rate of receiving an HLA‐incompatible unit was 21.3%. The risk of receiving an HLA‐incompatible unit rose from 4.8% after receipt of one unit to 36.5% after 10 units.ConclusionBlood collectors and hospitals should evaluate the potential TRALI risk against the benefit of a potentially expanded inventory of LTOWB before collecting plasma‐containing products from non‐HLA‐tested parous female donors.